LUT-017

LUT-017 is a novel small molecule B-Raf inhibitor developed by Lutris Pharma. It is designed for topical application to the skin and leverages the paradoxical effect of B-Raf inhibition in non-mutated cells to stimulate skin stem cell proliferation and accelerate wound healing. Unlike its use in oncology (where B-Raf inhibition leads to tumor shrinkage), topical application of LUT-017 in normal skin promotes regeneration and keratinocyte proliferation. The primary indication under investigation is for non-healing wounds such as venous leg ulcers, particularly targeting populations with diabetes, obesity, or limited mobility. As of now, development remains at the preclinical stage[1][4].

Other names

1,5-Isoquinolinediamine N1-[4-chloro-3]